M2 Archive: Preview


You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.


BioArctic's interim analysis of phase 1/2 study of SC0806 in patients with CSC injury halts spinal cord injury project

BioArctic AB (STO: BIOAB), a Swedish research-based biopharmaceutical company, reported on Monday the results of an interim analysis of a phase 1/2 study of SC0806 in patients with complete spinal cord injury.

Under this analysis, none of the patients showed an effect as measured by...  


If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search